iVexSol

Lexington, United States

IVexSol is a lentiviral vector production platform that supplies a consistent source of vectors for successful gene therapy programs.

$23.8M raised

Jan 2023

Series A

Manufacturing

Top Investors

Bristol-Myers SquibbCharles River Laboratories InternationalCasdin CapitalMassachusetts Life Sciences CenterBioLife Solutions

Founder Contacts

19,000+ verified contacts

Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about iVexSol

How much funding has iVexSol raised?

iVexSol has raised $23.8M in total funding. The most recent round was Series A. The last funding was announced in January 2023.

Who are iVexSol's investors?

iVexSol's investors include Bristol-Myers Squibb, Charles River Laboratories International, Casdin Capital, Massachusetts Life Sciences Center, BioLife Solutions.

Where is iVexSol headquartered?

iVexSol is headquartered in Lexington, United States.

What does iVexSol do?

IVexSol is a lentiviral vector production platform that supplies a consistent source of vectors for successful gene therapy programs.

What stage is iVexSol at?

iVexSol is at the Series A stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated January 26, 2023.

MLA

"iVexSol — Funding & Investors." VCBacked, January 26, 2023, https://www.vcbacked.co/company/ivexsol. Accessed June 8, 2026.

APA

VCBacked. (2023). iVexSol — Funding & Investors. Retrieved June 8, 2026, from https://www.vcbacked.co/company/ivexsol

Wikipedia (cite web)

{{cite web |title=iVexSol — Funding & Investors |url=https://www.vcbacked.co/company/ivexsol |website=VCBacked |access-date=June 8, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated January 26, 2023.

Similar Companies in Manufacturing

Trillium Renewable Chemicals

Knoxville